Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.
Porrello A, Leslie PL, Harrison EB, Gorentla BK, Kattula S, Ghosh SK, Azam SH, Holtzhausen A, Chao YL, Hayward MC, Waugh TA, Bae S, Godfrey V, Randell SH, Oderup C, Makowski L, Weiss J, Wilkerson MD, Hayes DN, Earp HS, Baldwin AS, Wolberg AS, Pecot CV. Porrello A, et al. Among authors: weiss j. Nat Commun. 2018 May 18;9(1):1988. doi: 10.1038/s41467-018-04355-w. Nat Commun. 2018. PMID: 29777108 Free PMC article.
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Weiss JM, Pennell N, Deal AM, Morgensztern D, Bradford DS, Crane J, West HJ, Lee C, Pecot C, Stevenson JP, Irvin W, Socinski M, Stinchcombe T, Villaruz LC, Muss HB. Weiss JM, et al. Cancer. 2020 Mar 1;126(5):1060-1067. doi: 10.1002/cncr.32573. Epub 2020 Jan 14. Cancer. 2020. PMID: 31943168 Free article. Clinical Trial.
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY, Sorrentino JA, Dragnev KH, Weiss JM, Owonikoko TK, Rytlewski JA, Hood J, Yang Z, Malik RK, Strum JC, Roberts PJ. Lai AY, et al. Among authors: weiss jm. J Immunother Cancer. 2020 Oct;8(2):e000847. doi: 10.1136/jitc-2020-000847. J Immunother Cancer. 2020. PMID: 33004541 Free PMC article.
Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Chera BS, Sheth SH, Patel SA, Goldin D, Douglas KE, Green RL, Shen CJ, Gupta GP, Moore DT, Grilley Olson JE, Weiss JM. Chera BS, et al. Among authors: weiss jm. Cancer. 2021 Dec 1;127(23):4447-4454. doi: 10.1002/cncr.33789. Epub 2021 Aug 11. Cancer. 2021. PMID: 34379792 Free article. Clinical Trial.
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Haddad RI, et al. Among authors: weiss j. J Immunother Cancer. 2022 Feb;10(2):e003026. doi: 10.1136/jitc-2021-003026. J Immunother Cancer. 2022. PMID: 35217573 Free PMC article.
5,585 results